Hydroxyurea for Sickle Cell Anemia: 30 Years of Progress & Global Challenges
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The study, involving over 17,600 participants, initially aimed to determine if semaglutide could reduce the risk of these events, but the results showed a statistically critically important, though modest, increase in risk within the treatment group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Key Findings and Data Breakdown
The SELECT trial followed participants for an average of 3.4 years. the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.5% of participants receiving semaglutide versus 5.8% in the placebo group. This translates to a hazard ratio of 1.13, indicating a 13% increased risk. While this difference is statistically significant, it’s crucial to understand the absolute risk increase is relatively small.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| Cardiovascular Death | 1.5 | 1.2 | 1.26 |
| Nonfatal Myocardial Infarction | 2.5 | 2.2 | 1.16 |
| Nonfatal Stroke | 2.5 | 2.4 | 1.06 |
| Composite Outcome (CV Death, MI, Stroke) | 6.5 | 5.8 | 1.13 |
Importantly, the study also noted a greater reduction in body weight in the semaglutide group (an average of 15% weight loss) and improvements in other cardiovascular risk factors like blood pressure and cholesterol. However, these benefits did not outweigh the observed increase in cardiovascular events within this specific patient population.
Who is Affected? Understanding the Patient Profile
The SELECT trial focused on adults with obesity (BMI of 30 or higher) *and* pre-existing cardiovascular disease,such as a history of heart attack,stroke,or peripheral artery disease. This is a critical distinction. The findings do *not* necessarily apply to individuals with obesity who do not have established cardiovascular issues, or to those using semaglutide for weight loss without this underlying health condition. The results raise particular concern for the millions of peopel with both obesity and cardiovascular disease who may be considering or are already using semaglutide.
What Does This mean? Implications for Patients and physicians
These findings necessitate a more cautious approach to prescribing semaglutide, and similar GLP-1 receptor agonists, to patients with established cardiovascular disease. A thorough risk-benefit assessment is now paramount. physicians should carefully consider the patient’s cardiovascular history, other risk factors, and the potential for choice treatments. Patients currently on semaglutide who have cardiovascular disease should discuss these findings with their doctor and not discontinue medication without medical advice.